Lysine‑specific demethylase 2 contributes to the proliferation of small cell lung cancer by regulating the expression of TFPI‑2

Cao,Yunfeng; Guo,Chunhui; Yin,Yanhai; Li,Xin; Zhou,Ling

doi:10.3892/mmr.2018.9047

Lysine‑specific demethylase 2 contributes to the proliferation of small cell lung cancer by regulating the expression of TFPI‑2

Authors:
- Yunfeng Cao
- Chunhui Guo
- Yanhai Yin
- Xin Li
- Ling Zhou
View Affiliations

Affiliations: Department of Oncology, Binzhou Central Hospital, Huimin, Shandong 251700, P.R. China, Department of Respiratory Medicine, Binzhou Central Hospital, Binzhou, Shandong 251700, P.R. China, Department of Respiratory Medicine, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
Published online on: May 22, 2018 https://doi.org/10.3892/mmr.2018.9047
Pages: 733-740
Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effect of lysine‑specific demethylase 2 (LSD2) in small cell lung cancer (SCLC) and explore its underlying regulatory mechanism. Cell growth was tested by MTT assay and mRNA and protein expression was determined by quantitative polymerase chain reaction (q‑PCR) and western blot analysis, respectively. Chromatin immunoprecipitation (ChIP) was used to investigate the degree of H3K4me2 enrichment in the promoter region of tissue factor pathway inhibitor‑2 (TFPI‑2). SCLC tissues and cell lines presented significantly higher expression of LSD2 and DNA methyltransferase 3B (DNMT3B) and lower expression of TFPI‑2 compared with the controls. In H1417 cells LSD2 overexpression increased the mRNA and protein expression of DNMT3B, while inhibiting the mRNA and protein expression of TFPI‑2. Following transfection with short interfering (si) RNA‑DNMT3B, the expression of TFPI‑2 increased in H1417 cells. The results of ChIP demonstrated that compared with the controls, H3K4me1 enrichment in the TFPI‑2 promoter region was to a lower degree in the H1417 cells with LSD2 overexpression and a higher degree in the H1417 cells with LSD2 silencing. MTT assays revealed that LSD2 overexpression significantly promoted the growth of H69, DMS‑114 and H1417 cells, which was contradictory to the effect on LSD2 silencing. Compared with the LSD2 overexpression cells, SCLC cells with simultaneous overexpression of LSD2 and TFPI‑2 demonstrated a decreased proliferation. These results suggest that LSD2 achieves a promoting effect on SCLC by indirectly regulating TFPI‑2 expression through the mediation of DNMT3B expression or through the regulation of the demethylation of H3K4me1 in the promoter region of the TFPI‑2 gene.

View Figures

View References

1	Coleman MH and Bueno R: Role of adjuvant chemotherapy in NSCLC (stages I to III). Surg Oncol Clin N Am. 20:757–767. 2011. View Article : Google Scholar : PubMed/NCBI
2	Pillai RN and Owonikoko TK: Small cell lung cancer: Therapies and targets. Semin Oncol. 41:133–142. 2014. View Article : Google Scholar : PubMed/NCBI
3	Arcaro A: Targeted therapies for small cell lung cancer: Where do we stand? Crit Rev Oncol Hematol. 95:154–164. 2015. View Article : Google Scholar : PubMed/NCBI
4	Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, Karlin DA, Faoro L, Scappaticci FA and Socinski MA: Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: Results from the SALUTE trial. J Clin Oncol. 29:2215–2222. 2011. View Article : Google Scholar : PubMed/NCBI
5	Hopkins-Donaldson S, Ziegler A, Kurtz S, Kurtz S, Bigosch C, Kandioler D, Ludwig C, Zangemeister-Wittke U and Stahel R: Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 10:356–364. 2003. View Article : Google Scholar : PubMed/NCBI
6	Tanaka N, Toyooka S, Soh J, Kubo T, Yamamoto H, Maki Y, Muraoka T, Shien K, Furukawa M, Ueno T, et al: Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. Lung Cancer. 76:32–38. 2012. View Article : Google Scholar : PubMed/NCBI
7	Tsou JA, Hagen JA, Carpenter CL and Laird-Offringa IA: DNA methylation analysis: A powerful new tool for lung cancer diagnosis. Oncogene. 21:5450–5461. 2002. View Article : Google Scholar : PubMed/NCBI
8	Karytinos A, Forneris F, Profumo A, Ciossani G, Battaglioli E, Binda C and Mattevi A: A novel mammalian flavin-dependent histone demethylase. J Biol Che. 284:17775–17782. 2009. View Article : Google Scholar
9	Fang R, Barbera AJ, Xu Y, Rutenberg M, Leonor T, Bi Q, Lan F, Mei P, Yuan GC, Lian C, et al: Human LSD2/KDM1b/AOF1 regulates gene transcription by modulating intragenic H3K4me2 methylation. Mol Cell. 39:222–233. 2010. View Article : Google Scholar : PubMed/NCBI
10	Chen L, Vasilatos SN, Qin Y, Oesterreich S, Davidson NE and Huang Y: Abstract 1385: New insights into the roles of histone lysine-specific demethylase 2 (LSD2) in breast cancer. AACR. 77:13852017.
11	Katz TA, Vasilatos SN, Oesterreich S, Chandran U, Davidson NE and Huang Y: Abstract 1052: Synergy between inhibition of novel histone demethylase (LSD2) and DNA methyltransferase (DNMT) and histone deacetylase (HDAC) in modulating gene expression and inhibiting growth in human breast cancer cells. AACR. 72:10522012.
12	Yang Y, Yin X, Yang H and Xu Y: Histone demethylase LSD2 acts as an E3 ubiquitin ligase and inhibits cancer cell growth through promoting proteasomal degradation of OGT. Mol Cell. 58:47–59. 2015. View Article : Google Scholar : PubMed/NCBI
13	Qin H, Chan MW, Liyanarachchi S, Balch C, Potter D, Souriraj IJ, Cheng AS, Agosto-Perez FJ, Nikonova EV, Yan PS, et al: An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules. BMC Syst Biol. 3:732009. View Article : Google Scholar : PubMed/NCBI
14	Chen L, Vasilatos SN, Qin Y, Katz TA, Cao C, Wu H, Tasdemir N, Levine KM, Oesterreich S, Davidson NE and Huang Y: Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression. Oncotarget. 8:81737–81753. 2017.PubMed/NCBI
15	Mino K, Nishimura S, Ninomiya S, Tujii H, Matsumori Y, Tsuchida M, Hosoi M, Koseki K, Wada S, Hasegawa M, et al: Regulation of tissue factor pathway inhibitor-2 (TFPI-2) expression by lysine-specific demethylase 1 and 2 (LSD1 and LSD2). Biosci Biotechnol Biochem. 78:1010–1017. 2014. View Article : Google Scholar : PubMed/NCBI
16	Konduri SD, Tasiou A, Chandrasekar N and Rao JS: Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol. 18:127–131. 2001.PubMed/NCBI
17	Cruickshanks HA, Vafadar-Isfahani N, Dunican DS, Lee A, Sproul D, Lund JN, Meehan RR and Tufarelli C: Expression of a large LINE-1-driven antisense RNA is linked to epigenetic silencing of the metastasis suppressor gene TFPI-2 in cancer. Nucleic Acids Res. 41:6857–6869. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kader F and Ghai M: DNA methylation-based variation between human populations. Mol Genet Genomics. 292:5–35. 2017. View Article : Google Scholar : PubMed/NCBI
19	Qu Y, Dang S and Hou P: Gene methylation in gastric cancer. Clin Chim Acta. 424:53–65. 2013. View Article : Google Scholar : PubMed/NCBI
20	Karlić R, Chung HR, Lasserre J, Vlahovicek K and Vingron M: Histone modification levels are predictive for gene expression. Proc Natl Acad Sci USA. 107:2926–2931. 2010. View Article : Google Scholar : PubMed/NCBI
21	Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, Ye Z, Lee LK, Stuart RK, Ching CW, et al: Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature. 459:108–112. 2009. View Article : Google Scholar : PubMed/NCBI
22	Gupta J, Kumar S, Li J, Krishna Murthy Karuturi R and Tikoo K: Histone H3 lysine 4 monomethylation (H3K4me1) and H3 lysine 9 monomethylation (H3K9me1): Distribution and their association in regulating gene expression under hyperglycaemic/hyperinsulinemic conditions in 3T3 cells. Biochimie. 94:2656–2664. 2012. View Article : Google Scholar : PubMed/NCBI
23	Katz TA, Vasilatos SN, Harrington E, Oesterreich S, Davidson NE and Huang Y: Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells. Breast Cancer Res Treat. 146:99–108. 2014. View Article : Google Scholar : PubMed/NCBI
24	Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, et al: Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: Implications for therapy. Cancer Res. 69:2065–2071. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wu D, Xiong L, Wu S, Jiang M, Lian G and Wang M: TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer. Lung Cancer. 76:106–111. 2012. View Article : Google Scholar : PubMed/NCBI
26	Zhang Q, Zhang Y, Wang SZ, Wang N, Jiang WG, Ji YH and Zhang SL: Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer. J Exp Clin Cancer Res. 31:12012. View Article : Google Scholar : PubMed/NCBI
27	Hu H, Chen X, Wang C, Jiang Y, Li J, Ying X, Yang Y, Li B, Zhou C, Zhong J, et al: The role of TFPI2 hypermethylation in the detection of gastric and colorectal cancer. Oncotarget. 8:84054–84065. 2017. View Article : Google Scholar : PubMed/NCBI
28	Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR and Goggins M: Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene. 24:850–858. 2005. View Article : Google Scholar : PubMed/NCBI
29	Wang S, Xiao X, Zhou X, Huang T, Du C, Yu N, Mo Y, Lin L, Zhang J, Ma N, et al: TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer. 10:6172010. View Article : Google Scholar : PubMed/NCBI
30	Konduri SD, Srivenugopal KS, Yanamandra N, Dinh DH, Olivero WC, Gujrati M, Foster DC, Kisiel W, Ali-Osman F, Kondraganti S, et al: Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. Oncogene. 22:4509–4516. 2003. View Article : Google Scholar : PubMed/NCBI
31	Hubé F, Reverdiau P, Iochmann S, Rollin J, Cherpi-Antar C and Gruel Y: Transcriptional silencing of the TFPI-2 gene by promoter hypermethylation in choriocarcinoma cells. Biol Chem. 384:1029–1034. 2003. View Article : Google Scholar : PubMed/NCBI